RNAi Therapeutics Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights

The RNAi TherapeuticsMarket was valued at US$ 1.5 billion in 2021 and is expected to reach US$ 3.2 billion by 2031. The market is expected to register a CAGR of 16.5% from 2023–2031. Rising Research & Development (R&D) activity is likely to remain key RNAi Therapeutics Market trends.

RNAi TherapeuticsMarket Analysis

RNAi Therapeutics in Cancer Therapy

RNAi technique is a new modality for cancer therapy, with several candidates being tested clinically. The significant advantage of RNAi for cancer therapy is its high specificity, with an infinite choice of genes that can be applied to cancer therapy. For example, RNAi therapeutics could interfere with angiogenesis, metastasis, chemoresistance of tumors, and proliferation of cancer cells. Additionally, 10 types of RNAi-based cancer therapeutics have entered the early stage clinical trials, demonstrating the potential capability of RNAi with specific gene-silencing efficacy for cancer treatment. Therefore, the aforementioned factors are responsible for influential RNAi therapeutics market growth during 2021-2031.

RNAi TherapeuticsMarket Overview

Technology, innovation, and smart technological solutions such as continue to influence RNAi therapeutics significantly. RNAi therapeutics in cancer therapy  and rising clinical trials for developing of innovative RNAi therapeuticsare the most influential factors responsible for RNAi Therapeutics Market growth. Rising Research & Development (R&D) activity is a key trend for RNAi Therapeutics Market growth. Imaging modalities for RNAi therapeuticswill provide lucrative market opportunity.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

RNAi Therapeutics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

RNAi TherapeuticsMarket Drivers and Opportunities

Rising Clinical Trials for Developing of Innovative RNAi Therapeutics to Favor Market

• In August 2023, Sirnaomics announced "STP707" RNAi therapeutics Clinical Phase 1, which demonstrated promising clinical potential for metastasized tumors. The clinical study was conducted in the US with the participation of multiple leading cancer centers, including Mayo Clinic Oncology, Emory Cancer Center, University of Southern California/Hoag, and Yale Cancer Center.
• Additionally, Alnylam company's has a robust pipeline of investigational RNAi therapeutics to address the needs of patients having limited or inadequate treatment options for disease that include: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases. The products include "ONPATTRO", "AMVUTTRA", "GLVLAARI", "OXLUMO", "Leqvio", "Vutrisiran", "Fitusiran", "Cemdisiran", "Zilebrsiran", "ALN-HSD", "Elebsiran", "Belcesiran", "ALN-APP", "ALN-TTRsc04", "ALN-APP", "ALN-KHK", "ALN-BCAT", "ALN-PNP”.

Therefore, rising clinical trials for RNAi therapeutics will contribute significantly in the coming years.

Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics Market– An Opportunity

Currently, multiple molecular imaging modalities have been applied in RNAi-related research, such as optical imaging (fluorescence and bioluminescence), Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), SPECT, and Positron Emission Tomography (PET). Also, molecular imaging of the therapeutic effects of RNAi is still at the preclinical stage, focussing on the visualization of marker gene expression levels among living animals. These imaging markers are mostly bioluminescent enzymes, where pharmacological activity can be accurately measured. Additionally, MRS also proves useful in evaluating the efficacy of RNAi-based therapies due to its potential to directly detect biological outcomes. Further, the MRS functions better than optical imaging in measuring the chemical shifts to certain compounds (e.g. choline) whose concentration in tissues or tumors can be altered by certain therapeutic interventions. Therefore, R&D activities provide lucrative market opportunities accounting considerable market share in the coming years for RNAi Therapeuticsmarket.

RNAi Therapeutics

Market Report Segmentation Analysis

Key segments that contributed to the derivation of the RNAi Therapeutics Market analysis are candidature and services.

• Based on Molecule Type, the RNAi Therapeutics Market is segmented into Small Interfering RNAs (siRNA) and MicroRNA (miRNA). The Small Interfering RNAs (siRNA) may hold a larger market share in 2023.
• Based on Application, the RNAi Therapeutics Market is segmented into genetic disorders, oncology, neurodegenerative disorders, cardiovascular, respiratory disorders, infectious diseases, renal diseases, and others. The oncology may hold a larger market share in 2023.
• Based on Route of Administration, the RNAi Therapeutics Market is segmented into intradermal injections, pulmonary delivery, intravenous injections, intraperitoneal injections, and others. The pulmonary delivery may hold a larger market share in 2023.
• Based on End User, the RNAi Therapeutics Market is segmented into diagnostic laboratories, research & academic laboratories, and hospitals. The research & academic laboratories may hold a larger market share in 2023.

RNAi Therapeutics Market Share Analysis by Geography

The geographic scope of the RNAi TherapeuticsMarket report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the RNAi Therapeutics Market. In North America, US accounts considerable share for RNAi therapeutics. Presence of top medical biotechnology and pharmaceutical players in the US. Additionally, presence of Contract Research Organizations (CROs) enhancing Research & Development (R&D) activities are one of the most influential factors responsible for market growth. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.  

RNAi Therapeutics

RNAi Therapeutics Market Regional Insights

The regional trends and factors influencing the RNAi Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses RNAi Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

RNAi Therapeutics Market Report Scope

RNAi Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics

The RNAi Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the RNAi Therapeutics Market are:

1. Alnylam Pharmaceuticals, Inc.,
2. Sanofi,
3. Olix Pharmaceuticals, Inc.,
4. GlaxoSmithKline Plc,
5. Benitec Biopharma,
6. Arbutus Biopharma Corporation,

Disclaimer: The companies listed above are not ranked in any particular order.

RNAi TherapeuticsMarket News and Recent Developments

The RNAi TherapeuticsMarket is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in them market for RNAi Therapeutics and strategies:

• In April 2024, Novartis, announced launching of "Leqvio" to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting thereby reducing the low-density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD).

RNAi TherapeuticsMarket Report Coverage and Deliverables

The “RNAi TherapeuticsMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles